Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. The Danish drugmaker is paying ...

Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential. ... Specifically, Wegovy is now approved to treat patients at risk of heart disease.

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ... and anti-amyloid therapy PRX004 in phase 2 for rare heart disease ATTR cardiomyopathy. ...

Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that ...

Novo Nordisk’sNOVO.B-2.58 % decrease; red down pointing triangle once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14% ...

Novo’s post-hoc data drop, which was published in the Lancet Friday, looked at heart failure outcomes in a total of 3,743 patients with a history of HFpEF across two semaglutide doses—2.4 mg ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% ...